NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)

NewAmsterdam Pharma has disclosed Non-Current Deffered Revenue across 3 years of filings, most recently posting $222000.0 for Q2 2024.

• Non-Current Deffered Revenue for Q2 2024 came in at $222000.0, down 97.9% year-over-year; the trailing twelve-month figure through Jun 2024 was $222000.0 (down 97.9% YoY), and the FY2023 annual result was $1.0 million, down 78.74% from the prior year.
• Non-Current Deffered Revenue came in at $222000.0 for Q2 2024 at NewAmsterdam Pharma, down from $444000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $10.6 million in Q2 2023 to a low of $222000.0 in Q2 2024.
• The 3-year median for Non-Current Deffered Revenue is $1.0 million (2023), against an average of $3.4 million.
• Across the five-year window, Non-Current Deffered Revenue tumbled 77.77% in 2023 and slumped 97.9% in 2024, its largest moves.
• NewAmsterdam Pharma's Non-Current Deffered Revenue stood at $4.6 million in 2022, then sank by 77.77% to $1.0 million in 2023, then tumbled by 78.21% to $222000.0 in 2024.
• The last three Non-Current Deffered Revenue figures came in at $222000.0 (Q2 2024), $444000.0 (Q1 2024), and $1.0 million (Q4 2023), per Business Quant data.